Orthocell Ltd has released a press release.
First Sales of Remplir Achieved in US$75m Canadian Market
Earlier from Orthocell
- Compelling 90% Success Rate for Remplir in Real World Study
- Q3 FY26 Investor Presentation
- First Surgical Use of Remplir in US Department of Defense
- OCC Secures Access to 221 U.S. Military Medical Centres